Jane Street’s Protara Therapeutics TARA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-156,135
Closed -$832K 12947
2025
Q4
$832K Buy
156,135
+110,889
+245% +$617K ﹤0.01% 6528
2025
Q3
$197K Buy
45,246
+18,350
+68% +$59.4K ﹤0.01% 9698
2025
Q2
$81.5K Sell
26,896
-64,559
-71% -$223K ﹤0.01% 9038
2025
Q1
$390K Buy
91,455
+53,721
+142% +$240K ﹤0.01% 7335
2024
Q4
$199K Buy
+37,734
New +$122K ﹤0.01% 8415
2024
Q3
Sell
-12,850
Closed -$26.7K 10385
2024
Q2
$26.7K Buy
+12,850
New +$37.6K ﹤0.01% 9017
2021
Q3
Sell
-13,678
Closed -$133K 10704
2021
Q2
$133K Buy
+13,678
New +$155K ﹤0.01% 9125
2019
Q3
Sell
-258
Closed -$4K 5733
2019
Q2
$4K Buy
+258
New +$4.56K ﹤0.01% 5054

Other funds holding TARA

Jane Street's TARA Position: Q1 2026 in Review

Jane Street sold out of Protara Therapeutics (TARA) in Q1 2026, closing a stake of 156,135 shares — an estimated $832K sold.

Jane Street first reported a position in TARA in Q2 2019 and held it in 8 quarters. The position peaked at $832K in Q4 2025. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • Jane Street reported no remaining Protara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 156,135 Protara Therapeutics shares in Q1 2026, an estimated $832K.
  • Jane Street first reported a position in Protara Therapeutics in Q2 2019 and held it in 8 quarters.
  • Jane Street's Protara Therapeutics position peaked at $832K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.